Kastelein J.J.P. Van Leuven S.I. Burgess L. Evans G.W. Kuivenhoven J.A. Barter P.J. Revkin J.H. Grobbee D.E. Riley W.A. Shear C.L. Duggan W.T. Bots M.L.
(2007)
Background: Torcetrapib, an inhibitor of cholesteryl ester transfer protein, may reduce atherosclerotic vascular disease by increasing levels of high-density lipoprotein (HDL) cholesterol. Methods: A total of 850 patients ...